daniluromer

EB01 (daniluromer) is a novel non-steroidal anti-inflammatory small molecule drug developed as a topical cream for the treatment of moderate-to-severe chronic allergic contact dermatitis (ACD). Its mechanism of action is inhibition of secretory phospholipase A2 (sPLA2), which blocks the inflammatory process at its inception. Clinical studies have shown that EB01 cream significantly improves symptoms such as redness, pruritis/itching, fissures, scaling, and dryness compared to placebo. The drug has demonstrated efficacy and safety in Phase 2 trials with no serious treatment-related adverse events reported. It is positioned as a potential leading therapy option for chronic ACD patients who require long-term management without the risks associated with corticosteroids or calcineurin inhibitors[1][2][3][4][7].

Other names

daniluromer